Novaterra

Ma #BASTAAA with fake startups, AI, SaaS and bottle caps, we need to re-build a continent back if we don't wanna be an open museum of grandpas very soon. We are not producing anymore. Founders who want to build, please text me / us at Novaterra, where we are trying to create a big group of R&D and industrial companies. ps. We only invest if you and your team are spending more than 50% of the time not sitting in front of a computer. Let's #build 🔨🔨🔨

💡 Join Lina Gaydarova of Novaterra at RESI Europe, co-organized with Biocat, BioRegion of Catalonia, as she speaks on the Seed Funds panel. This discussion will bring together investors who specialize in early-stage life sciences and healthcare to share insights on: 🔹 The role of seed investors in shaping the early-stage ecosystem 🔹 Strategies for identifying high-potential ventures and mitigating risk 🔹 Key focus areas within life sciences and healthcare 🔹 How seed funds help startups scale and grow 📍 Don’t miss this opportunity to learn from investors shaping the future of healthcare innovation. Register by Friday to save €200! https://lnkd.in/eYfMpbfa #RESIEurope #LifeSciences #HealthcareInvesting #Biotech

We’re proud to announce we got a minority stake in Limenet, an environmental tech company that captures CO₂ and converts it into calcium bicarbonate for safe ocean storage. At Novaterra, we invest in companies able to solve real problems and systemic challenges, by industrial engineering and science. This process not only reduces carbon in the atmosphere but also helps rebalance ocean pH levels, offering critical benefits to marine ecosystems. Good luck to the CEO, Stefano Cappello and the whole team! Learn more about why we’re backing Limenet and its mission: https://lnkd.in/egfgJmUH.

At Novaterra, decisions are built on deep understanding, rigorous selection and, most importantly, transparency. Last week, we welcomed more than 100 angels in our closed-door investment committee session held by our CEO Giuseppe Joe Balzano and portfolio manager Lina Gaydarova, where we explored a highly technical solution in one of our favourite industries: the nuclear supply chain. This wasn’t just a pitch: it was a strategic meeting to show how our team evaluates deep tech ventures beyond the hype that often characterises the VC industry. Angels had the chance to ask questions and deep dive into the company together with two VC expert guests for this meeting: Luigi Di Piazza, and Oliver Lamb. Thanks for having helped us with valuable feedback and technical analyses. This is what sets Catalisi, our exclusive angels’ club, apart, as not all investors have access to the same information, nor do all communities operate in the same way. www.novaterra.io/catalisi

After some months building Novaterra in stealth (great announcements soon!), I decided to share a personal note today. It's hard to fully share yourself, because you have to compromise on how much you want to share. On the other side, I learned how the personal soul, and background, of a Founder is everything for its company. A company is just a propagation of the people who build it. Here we go, why I am an investor and why I am building this 🏴☠️ Giu

We are proud to start 2025 by revealing our new portfolio company NK:IO, a London-based biotech company, spin off of Imperial College London advancing the frontier of cell therapy for solid tumours. NK:IO is tackling one of the most pressing challenges in oncology: creating safer and more effective treatments for cancers like ovarian cancer, which have limited options and devastating outcomes. Their innovative platform harnesses Natural Killer (NK) cells, leveraging a proprietary process to produce them at scale and in peak cytotoxic form. Unlike traditional therapies, NK cells offer a safer, non-genetically modified approach to targeting cancerous cells while sparing healthy tissue. Behind this vision is an exceptional team, including CEO Richard Hopkins, a leader in cell therapy with a proven track record, and co-founders Professor Hugh Brady, Professor Matt Fuchter, and Dr. Mike Romanos, whose scientific and industry expertise provides the foundation for NK:IO’s progress. We are excited to support NK:IO as they advance toward the next stage of development and wish the team every success in bringing their vision to life. 🏴☠️🏴☠️🏴☠️ --- Investment thesis in the comments.

Europe, time to #build again. Back to factories and labs. We must immediately focus on manufacturing, biotech, defense, and space and create global champions of defensible technology.

Today we announce we gained control of Catalisi, a private community of angel investors with over 350 active investors and 7 deals done in the last year alone. www.novaterra.io/catalisi When we ideated Novaterra, our vision was to create more than just a financial firm: we set out to build a movement of individuals dedicated to directing capital toward exponential technologies and groundbreaking science. By joining Catalisi:   • You gain access to the same opportunities Novaterra funds directly.  • You become part of an exclusive community of like-minded individuals committed to backing companies with an exponential impact.  • You receive the same top-notch deal flow typically reserved for institutional investors at no additional costs. This community is for those who believe that progress demands action and, most importantly, that every small contribution counts. Check the website for more. Time to #build, together!

🏴☠️🏴☠️🏴☠️ We are proud to introduce Biocentis, a company we partnered with earlier this year, now part of our portfolio. A biotech spin-off from Imperial College London, Biocentis is developing sustainable insect control solutions aimed at tackling major global challenges in agriculture and public health. Their precision genetic technology targets harmful insect populations without impacting other species or the environment, aligning with our commitment to improving our Planet's health with scientific innovation. Congratulations, and best of luck to CEO Giorgio Rocca and the whole team Andrew Hammond Kevin Gorman Andrea Crisanti! [Link to the investment thesis in the comments]

🏴☠️🏴☠️🏴☠️ We are pleased to announce we acquired a minority interest in Modulate Bio, a Harvard University spin-out advancing novel treatments for epilepsy, tremors, and other neurological disorders. We will create next-gen therapies that provide efficacy without the side effects common to other neuro drugs. The company is advancing small molecule therapies for epilepsy and essential tremor, and the proprietary algorithm helps create significant upside to develop further medicines across anxiety, depression, PTSD, and other movement disorders. Congratulations, and best of luck to CEO Andrew Thomson, CSO Dario Doller, and the entire team! [Link to the investment thesis in the comments]